RxDoctor Payments Data

John Bahadorani, MD

Cardiovascular Disease · la Jolla, CANPI 1780883082

Payments from drug & device makers

$110,228in general payments, 2019–2025

Across 971 payments — averaging $113.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • CSL Behring$61K
  • Biotronik Inc.$14K
  • Astellas Pharma US Inc$9K
  • Penumbra, Inc.$3K
  • Chiesi USA, Inc.$2K
  • Abbott$2K
  • plus $20K from 54 others

What the payments were for

  • Speaking & faculty fees$16,72534%
  • Travel & lodging$3,0486%
  • Food & beverage$29,47660%
  • Education$1250%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
CSL Behring29$60,855
Biotronik Inc.121$14,342
Astellas Pharma US Inc21$8,640
Penumbra, Inc.3$2,693
Chiesi USA, Inc.22$2,345
Abbott39$1,851
AstraZeneca16$1,610
Boston Scientific48$1,524
Amgen53$1,207
Shockwave Medical, Inc7$1,199
Abiomed22$1,148
Novartis71$1,098
E.r. Squibb & Sons, L.L.C.59$871
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)36$696
Impulse Dynamics (USA) Inc.26$676
Alnylam Pharmaceuticals Inc.23$657
Sanofi-aventis U.S. LLC30$598
Pfizer33$573
Medtronic(2 entities)15$540
AOP Health US, LLC1$525
Boehringer Ingelheim27$512
Merck23$501
Inari Medical, Inc.15$474
Cardiovascular Systems Inc.7$469
Novo Nordisk21$391
Johnson & Johnson21$358
Amarin Pharma, Inc.17$293
Scpharmaceuticals Inc.13$287
Regeneron Healthcare Solutions, Inc.17$279
Bayer10$239
Kestra Medical Technology Services, Inc.12$226
Otsuka America Pharmaceutical, Inc.9$213
Esperion Therapeutics, Inc.12$210
Kiniksa Pharmaceuticals International, PLC16$204
Cardiva Medical, Inc.8$181
Kiniksa Pharmaceuticals, Ltd.9$167
Stryker5$159
Cvrx, Inc.8$155
Biosense Webster, Inc.1$150
Atricure, Inc.6$149
Edwards Lifesciences2$143
Acutus Medical, Inc.1$130
Actelion Pharmaceuticals US, Inc.3$105
Tactile Systems Technology Inc7$101
Azurity Pharmaceuticals, Inc.3$75
Acist Medical Systems, Inc.3$60
Arbor Pharmaceuticals, Inc.4$58
Altathera Pharmaceuticals LLC1$43
Bridgebio Pharma, Inc.2$32
Preventice Services, LLC2$32
Cleerly, Inc.1$28
Bardy Diagnostics, Inc.2$26
Bristol Myers Squibb1$23
Infobionic, Inc1$21
Corcept Therapeutics1$20
GSK1$17
Lundbeck LLC1$15
Philips North America LLC1$14
Itamar Medical Inc1$14
Gilead1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$110,228 in reported general payments places this provider in the 90th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$664,150
Medicare patients
794
Services billed
5,739

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban252$315,835
XareltoRivaroxaban127$148,903
Repatha SureclickEvolocumab97$79,691
EntrestoSacubitril/Valsartan40$54,080
MultaqDronedarone Hcl26$50,815
BrilintaTicagrelor44$33,527
NexletolBempedoic Acid16$12,523
VascepaIcosapent Ethyl12$11,014
Repatha SyringeEvolocumab14$10,783
Ranolazine ErRanolazine89$6,339
Valsartan227$6,326
Rosuvastatin Calcium393$5,250
Metoprolol Succinate301$3,671
Amiodarone Hcl66$3,402
Atorvastatin Calcium348$3,338

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$573$315,835252 claims
Johnson & JohnsonXarelto$358$148,903127 claims
NovartisEntresto$1,098$54,08040 claims
Sanofi-aventis U.S. LLCMultaq$598$50,81526 claims
AstraZenecaBrilinta$1,610$33,52744 claims
Esperion Therapeutics, Inc.Nexletol$210$12,52316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in la Jolla

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →